摘要:
The invention relates to the use of a Factor VIIa-related polypeptide for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, in particular a bleeding episode, said medicament being for subcataneous or intramuscular administration.
摘要:
The present invention relates to novel human coagulation Factor Vila variants having substitutions of one or more amino acids at a position selected from the group consisting of position 172, 173, 175, 176, 177, 196, 197, 198, 199, 200, 203, 235, 237, 238, 239, 240, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 297, 299, 319, 320, 321, 327, 341, 363, 364, 365, 366, 367, 370, 373 corresponding to amino acid positions of SEQ ID NO:1 and wherein said Factor VII polypeptide exhibits increased resistance to inactivation by an endogenous inhibitor of said FVII polypeptide relative to wild-type human FVIIa.
摘要翻译:本发明涉及新的人凝血因子VIIa变体,其在选自下列的位置中具有一个或多个氨基酸的取代:位置172,173,175,176,177,196,197,198,199,200,2203 ,235,237,238,239,240,286,287,288,289,290,291,292,293,294,295,297,29,39,320,321,327,341,363,364,365,346 ,366,367,370,373,其对应于SEQ ID NO:1的氨基酸位置,并且其中所述因子VII多肽相对于野生型人FVIIa表现出对所述FVII多肽的内源性抑制剂的失活的增强的抗性。
摘要:
Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.
摘要:
A method for transamidating a peptide substrate having a P.sub.1 amino acid residue with a positively charged side chain. According to the invention, carboxypeptidase Y is modified to substitute at least one amino acid having a negatively charged side chain in an S.sub.1 subsite. Additionally, the modified carboxypeptidase Y can include substituted amino acid residues in an S.sub.1 ', S.sub.2 and/or S.sub.3 subsite to accommodate a specific peptide substrate.
摘要:
The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.